HK1182384A1 - Crystalline forms of kinase inhibitors - Google Patents

Crystalline forms of kinase inhibitors

Info

Publication number
HK1182384A1
HK1182384A1 HK13109691.8A HK13109691A HK1182384A1 HK 1182384 A1 HK1182384 A1 HK 1182384A1 HK 13109691 A HK13109691 A HK 13109691A HK 1182384 A1 HK1182384 A1 HK 1182384A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
crystalline forms
crystalline
forms
kinase
Prior art date
Application number
HK13109691.8A
Other languages
English (en)
Chinese (zh)
Inventor
Geoff G Z Zhang
Paul J Brackemeyer
Ahmad Y Sheikh
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of HK1182384A1 publication Critical patent/HK1182384A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK13109691.8A 2010-06-09 2013-08-20 Crystalline forms of kinase inhibitors HK1182384A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35305810P 2010-06-09 2010-06-09
PCT/US2011/039582 WO2011156461A1 (en) 2010-06-09 2011-06-08 Crystalline forms of kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1182384A1 true HK1182384A1 (en) 2013-11-29

Family

ID=44454740

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13109691.8A HK1182384A1 (en) 2010-06-09 2013-08-20 Crystalline forms of kinase inhibitors

Country Status (18)

Country Link
US (2) US8357804B2 (xx)
EP (1) EP2580219B1 (xx)
JP (1) JP5711814B2 (xx)
KR (1) KR20130112855A (xx)
CN (1) CN103025741A (xx)
AR (1) AR083722A1 (xx)
AU (1) AU2011264899B2 (xx)
BR (1) BR112012031469A2 (xx)
CA (1) CA2802064A1 (xx)
ES (1) ES2537708T3 (xx)
HK (1) HK1182384A1 (xx)
MX (1) MX2012014385A (xx)
NZ (1) NZ605436A (xx)
RU (1) RU2012157471A (xx)
SG (1) SG186249A1 (xx)
TW (1) TWI492949B (xx)
WO (1) WO2011156461A1 (xx)
ZA (1) ZA201209647B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021020367A2 (pt) 2019-04-11 2021-12-07 Angion Biomedica Corp Formas sólidas de (e)-3-[2-(2-tienil)vinil] -1h-pirazol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
GB0402518D0 (en) * 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
US20070135387A1 (en) * 2005-12-08 2007-06-14 Michaelides Michael R Inhibitors of protein kinases
TWI438205B (zh) * 2008-03-05 2014-05-21 Methylgene Inc 蛋白質酪胺酸激酶活性抑制劑
WO2010065825A2 (en) * 2008-12-05 2010-06-10 Abbott Laboratories Kinase inhibitors with improved cyp safety profile

Also Published As

Publication number Publication date
CA2802064A1 (en) 2011-12-15
JP5711814B2 (ja) 2015-05-07
JP2013528220A (ja) 2013-07-08
SG186249A1 (en) 2013-01-30
WO2011156461A1 (en) 2011-12-15
ES2537708T3 (es) 2015-06-11
RU2012157471A (ru) 2014-07-20
TWI492949B (zh) 2015-07-21
US8357804B2 (en) 2013-01-22
AR083722A1 (es) 2013-03-20
EP2580219B1 (en) 2015-02-25
BR112012031469A2 (pt) 2016-11-01
KR20130112855A (ko) 2013-10-14
CN103025741A (zh) 2013-04-03
AU2011264899B2 (en) 2015-01-22
MX2012014385A (es) 2013-05-01
US20120149726A1 (en) 2012-06-14
TW201204736A (en) 2012-02-01
AU2011264899A1 (en) 2013-01-10
EP2580219A1 (en) 2013-04-17
US8592589B2 (en) 2013-11-26
US20130136804A1 (en) 2013-05-30
NZ605436A (en) 2014-11-28
ZA201209647B (en) 2014-02-26

Similar Documents

Publication Publication Date Title
HK1259135A1 (zh) Vmat2的苯並喹啉酮抑制劑
ZA201208373B (en) Compounds useful as inhibitors of atr kinase
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
HK1222647A1 (zh) 激酶抑制劑
HK1192247A1 (zh) 作為激酶抑制劑的雜環化合物
ZA201204136B (en) Pteridinones as inhibitors of polo-like kinase
HK1177205A1 (en) Oxazole kinase inhibitors
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
HUE048834T2 (hu) Kináz inhibitorok
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
IL225605A0 (en) Polo-like kinase inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
ZA201206456B (en) Uses of dgati inhibitors
IL229028A0 (en) Kinase inhibitors
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
HK1199873A1 (en) Kinase inhibitors
IL220187A0 (en) Inhibitors of sphingosine kinase
EP2758387A4 (en) Pyridine compounds as kinase inhibitors
HK1182383A1 (zh) 激酶抑制劑的結晶形式
EP2531197A4 (en) SOLID FORMS OF MACROCYCLIC CHINESE INHIBITORS
ZA201300009B (en) Oral formulation of kinase inhibitors
HK1182384A1 (en) Crystalline forms of kinase inhibitors
HK1179255A1 (en) Crystalline forms of kinase inhibitors
GB201009730D0 (en) Kinase inhibitor compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190607